Examples of Oligonucleotide Drug in a sentence
Isis will notify Elan in writing of Isis' good faith intention to manufacture or have manufactured an Oligonucleotide Drug incorporating any Elan Intellectual Property.
If Elan fails to respond to Isis' notice within the [***] or if Elan declines in writing to exercise its right of first negotiation, then, Isis will be free to manufacture and supply (either on its own or with a third party) the Oligonucleotide Drug.
The draft guidance, when finalized, will represent the current thinking of FDA on ‘‘IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations.’’ It does not establish any rights for any person and is not binding on FDA or the public.You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations.
If Elan wishes to manufacture the Oligonucleotide Drug incorporating any Elan Intellectual Property, the parties will negotiate in good faith the terms of a manufacturing agreement.
If despite good faith negotiations, Elan and Isis do not reach agreement within [***] from Elan's exercise of its right of first negotiation, then Isis will be free to manufacture and supply (either on its own or with a third party) the Oligonucleotide Drug.
The draft guidance, when finalized, will represent the current thinking of FDA on “IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations.” It does not establish any rights for any person and is not binding on FDA or the public.
Elan will have [***] from the receipt of such notice to notify Isis in writing whether or not Elan wishes to negotiate with Isis regarding the manufacture of the Oligonucleotide Drug.
The draft guidance, when finalized, will represent the current thinking of FDA on “IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations.” It does not establish any rights for any person and is not binding on FDA or the public.
The effects of different modifications and scale on the manufacturing process as well as techniques for developing scaled-down process models will be discussed.9:00 Introduction to the TutorialLubomir Nechev, Ph.D., Senior Director, Process Chemistry,Alnylam Pharmaceuticals, Inc., USA9:10 A History of DNA/RNA SynthesizersJeffrey Christopher Strauss, Vice President, BioAutomation Corp., USA9:50 Challenges in the Preparation and Analysis of Conjugated Oligonucleotide Drug CandidatesKenneth W.